The #1 sales methodology platform
RealPage + MEDDICC
Lumina changed what RealPage sells. The question now is whether the field can sell it.
An AI workforce platform doesn't close the way a SaaS module does. The buyer is further up, evaluating capital allocation rather than feature fit. The forecast has to hold up in a board room, not just a pipeline review.
Most sales teams at this inflection point aren't under-talented. They're under-equipped.
-1.png)
Lumina moved RealPage into a different category. The sales motion is catching up.
When your reps are busier than they've ever been, you want to walk into reviews being able to call the numbers with pure confidence. But when deals slip, they slip late, after they were already in the commit.
And the slips cost more than they used to. Every soft quarter gets weighed against a competitor about to go public clean and profitable. The pressure from the top is real, and it's on a clock.
Which leaves one question: can the field actually close the deals you're betting the company's next chapter on?
Right now, too many can't. Not because the team isn't good, but because no one has given them a way to run a deal this complex on purpose.
The playbook your competitors already use
The highest-performing sales organizations don't leave qualification and deal strategy to individual rep judgment.
MEDDPICC gives every seller a common language for identifying Economic Buyers, building Champions, qualifying opportunities, and navigating complex buying processes.
It's why companies like Salesforce, Adobe, CrowdStrike, and many of today's highest-performing enterprise revenue teams have adopted MEDDPICC as a core part of how they sell.
When execution consistency matters, methodology becomes a competitive advantage.
Why now?
This isn't a "nice-to-have methodology" conversation. It's an 18-month window.
Entrata will price its IPO into a market that rewards clean, profitable growth and every quarter your attainment lags and your forecast wobbles is a quarter that comparison gets less flattering.
Wakeham needs a credible commercial story for the next chapter. The board needs proof the org can execute at Lumina-level complexity. And Thoma Bravo needs the metrics that price a strong exit: attainment, productivity, NRR, forecast accuracy.
MEDDICC moves all four. Higher quota attainment. Shorter, cleaner cycles on complex deals. A forecast you can defend in a board meeting. And a field that can finally sell the transformation you've already built.
The product is ready. Let's get the motion ready too.
Hear Testimonials from GTM Teams
An efficient, scalable, and repeatable way to empower our GTM teams.
The immediate impact has been impressive.
With MEDDICC, we increased our average deal-size by 45%.
